Osprey Medical
  • DyeVert™
    • DyeVert™ PLUS EZ
    • Instructions for Use – United States Only
  • Be Kind to Kidneys™
  • Patients
    • About Your Kidneys
    • Patients at Risk
    • Kidney Kindness in the Cath Lab
    • Martha’s Story
    • DyeVert™ Plus System
  • International
    • DyeVert™ PLUS EZ
    • DyeVert™ Power XT
    • Instructions for Use – International
    • Instructions for Use – Australia
    • Instructions for Use – Canada
  • About Us
    • Management
    • Board of Directors
    • News
    • Patents
  • Investors
    • Financial Information
    • Releases
    • Events & Presentations
    • Stock Information
    • Corporate Governance
    • Contact Us
  • Search
  • Menu Menu
News
DyeVert™ PLUS System

Osprey Medical Receives US FDA Clearance for DyeVert™ Plus

March 9, 2017/in News

Osprey Medical today announced that it has received US FDA 510(k) clearance for its advanced DyeVert™ PLUS Contrast Reduction System. This new platform augments Osprey’s current technology with the capability to actively manage dye administration during coronary interventions.

DyeVert PLUS received European CE Mark in 4Q 2016. The company further validated its dye savings capabilities through initial market testing with multiple physicians in Germany and Italy, which showed a 44% contrast reduction. The product received strong positive feedback on the utility of real-time contrast monitoring and ease-of-use.

Read more

Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on LinkedIn
  • Share by Mail
https://ospreymed.com/wp-content/uploads/2017/04/DyeVert-PLUS-System.jpg 733 813 Rob Coleman https://ospreymed.com/wp-content/uploads/2021/03/osprey-logo-448w.png Rob Coleman2017-03-09 01:40:312017-07-05 20:13:10Osprey Medical Receives US FDA Clearance for DyeVert™ Plus

Osprey Medical Events

NCDR 2019 Annual Conference
March 13-15, 2019
New Orleans, LA

ACC.19
March 16-18, 2019
New Orleans, LA

SCAI Conference
May 19-22, 2019
Las Vegas, NV

TCT 2019
September 25-29, 2019
San Francisco, CA

Recent Posts

  • Osprey receives Supplier Horizon Award from Premier Inc
  • GE Healthcare to Distribute Osprey Medical’s Technology to Address Angiography Based Acute Kidney Injury (AKI)
  • US Government to Transform Kidney Care
  • AKI Burden of Illness Data Presented at Premier® Breakthroughs Conference
  • Osprey Medical, Inc. Awarded Premier Purchasing Agreement for DyeVert™ PLUS Contrast Reduction System

Archives

  • September 2020
  • July 2020
  • July 2019
  • June 2019
  • December 2018
  • September 2018
  • June 2017
  • March 2017
  • November 2016
  • October 2016
  • May 2016

© 2022 Osprey Medical Inc. All rights reserved.
Osprey Medical, DyeVert, DyeMINISH, and Be Kind to Kidneys are registered trademarks of Osprey Medical, Inc. in the United States and other countries.

Osprey YouTubeOsprey TwitterOsprey Facebook

Contact     Resources     Privacy     Terms of Use

Contact     Resources     Privacy     Terms of Use

Osprey Introduces DyeVert PLUS at TCT DyeVert™ PLUS System DyeVert Plus Cutting Down on Dye May Make Heart Procedures Safer for Kidney Patients
Scroll to top

Analyst Coverage Disclaimer Please note that any opinions, esimates or forecasts regarding Osprey Medical's performance made by analysts mentioned on this website are theirs alone and do not represent opinions, forecasts or predictions of Osprey Medical or its management. Osprey Medical does not by its reference to any analysts imply its endorsement of or concurrence with their information, conclusions, or recommendations. Information provided by analysts is subject to change, and Osprey Medical cannot guarantee its accuracy.

Check if you have read and acknowledged.